Sage Therapeutics, Inc. (SAGE)

Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Sage Therapeutics, Inc. (“Sage” or “the Company”) (NYSE: SAGE). Investors who purchased Sage securities are encouraged to obtain additional information and assist the investigation.

The investigation concerns whether Sage has violated federal securities laws. 

Investigation Details: 

On August 4, 2023, Sage issued a press release disclosing that the U.S. Food and Drug Administration (“FDA”) had approved “ZURZUVAETM (zuranolone) 50 mg for adults with postpartum depression (PPD)” only, and had “issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for zuranolone in the treatment of adults with major depressive disorder (MDD). The CRL stated that the application did not provide substantial evidence of effectiveness to support the approval of zuranolone for the treatment of MDD and that an additional study or studies will be needed.”  On this news, Sage’s stock price fell $19.35 per share, or 53.6%, to close at $16.75 per share on August 7, 2023. 

What’s Next? 

If you are aware of any facts relating to this investigation or purchased Sage securities, you can assist this investigation. You can also contact Peretz Bronstein or his law clerk and client relations manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660.   

Why Bronstein, Gewirtz & Grossman: 

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.  Our firm has recovered hundreds of millions of dollars for investors nationwide.  

Attorney advertising. Prior results do not guarantee similar outcomes. 


Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Nathanson
212-697-6484 | [email protected]